The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications.

Stress responses have been posited to be a key component of mental health and disease by playing essential roles both in normal adaptive processes and maladaptive physiological responses that in part underlie the pathogenesis of certain subtypes of mood and anxiety disorders. Early research focused on delineating the function of the hypothalamic-pituitary-adrenal (HPA) axis and subsequently examined its role in mediating the mammalian stress responses and its hyperactivity in depression. Much evidence now supports an important function of the biological mediators of this system in relation to not only depression, but also anxiety, substance abuse, and psychotic disorders, and implicates several components of this system as areas of intervention for novel pharmacotherapy. Perhaps the best studied central nervous system (CNS) component of this system is corticotropin-releasing factor (CRF), and considerable research has focused on its role in the HPA axis, as well in extrahypothalamic brain regions.

[1]  S. Heinrichs,et al.  Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective Antagonist , 2002, Neuropsychopharmacology.

[2]  C. Nemeroff,et al.  The link between childhood trauma and depression: Insights from HPA axis studies in humans , 2008, Psychoneuroendocrinology.

[3]  T. Delmonte,et al.  Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder , 2010, Depression and anxiety.

[4]  G. Koob,et al.  Corticotropin Releasing Factor Receptor 1–Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development , 1998, Neuron.

[5]  P. Moran,et al.  Clinical and Psychosocial Origins of Chronic Depressive Episodes , 1994, British Journal of Psychiatry.

[6]  C. Nemeroff,et al.  Hypercortisolemia and depression. , 2005, Psychosomatic medicine.

[7]  F. Ohl,et al.  Differential disinhibition of the neonatal hypothalamic– pituitary–adrenal axis in brain‐specific CRH receptor 1‐knockout mice , 2006, The European journal of neuroscience.

[8]  S. Maier,et al.  The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress* *This research was supported by NIMH Grant MH-50479 and the Undergraduate Research Opportunities Program at the University of Colorado at Boulder. , 1999, Endocrinology.

[9]  C. Nemeroff,et al.  The Dexamethasone/Corticotropin-Releasing Factor Test in Men with Major Depression: Role of Childhood Trauma , 2008, Biological Psychiatry.

[10]  T. Lovenberg,et al.  Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Koob,et al.  Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide , 2002, Brain Research.

[12]  C. Nemeroff,et al.  Long-Term Consequences of Neonatal Rearing on Central Corticotropin-Releasing Factor Systems in Adult Male Rat Offspring , 2005, Neuropsychopharmacology.

[13]  P. Gold,et al.  Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress , 2002, Pharmacology Biochemistry and Behavior.

[14]  Thomas Meitinger,et al.  Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment , 2004, Nature Genetics.

[15]  C. Donaldson,et al.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Ressler,et al.  Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes , 2009, Molecular Psychiatry.

[17]  M. Geyer,et al.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice , 2003, Psychopharmacology.

[18]  W. Vale,et al.  Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. , 2000, Endocrinology.

[19]  N. Kalin,et al.  Stimulation of Lateral Septum CRF2 Receptors Promotes Anorexia and Stress-Like Behaviors: Functional Homology to CRF1 Receptors in Basolateral Amygdala , 2007, The Journal of Neuroscience.

[20]  Anne W. Schmidt,et al.  CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Akil,et al.  Neuropeptide Concentrations in the Cerebrospinal Fluid of Depressed Patients Treated with Electroconvulsive Therapy , 1991, British Journal of Psychiatry.

[22]  Florian Holsboer,et al.  Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. , 2003, Journal of psychiatric research.

[23]  D. Overstreet,et al.  Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. , 2004, European journal of pharmacology.

[24]  M. Geyer,et al.  Corticotropin-Releasing Factor Receptors CRF1 and CRF2 Exert Both Additive and Opposing Influences on Defensive Startle Behavior , 2004, The Journal of Neuroscience.

[25]  T. Bártfai,et al.  A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. , 1996, European journal of pharmacology.

[26]  J. Harro,et al.  The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in therat , 2001, Neuropeptides.

[27]  Mingsheng Huang,et al.  Corticotropin‐releasing factor receptor type 1 mediates stress‐induced relapse to opiate dependence in rats , 2000, Neuroreport.

[28]  W. Vale,et al.  Primary structure of corticotropin-releasing factor from ovine hypothalamus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Vaughan,et al.  Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Goeders,et al.  Effects of the CRH Receptor Antagonist CP-154,526 on Intravenous Cocaine Self-administration in Rats , 2000, Neuropsychopharmacology.

[31]  Lin Lu,et al.  Differential roles of corticotropin‐releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence , 2000, The European journal of neuroscience.

[32]  M. Rosenfeld,et al.  A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Corman,et al.  Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist. , 1997, Journal of medicinal chemistry.

[34]  W. Vale,et al.  The Effect of Lateral Septum Corticotropin-Releasing Factor Receptor 2 Activation on Anxiety Is Modulated by Stress , 2006, The Journal of Neuroscience.

[35]  S. Dube,et al.  Long-term consequences of childhood sexual abuse by gender of victim. , 2005, American journal of preventive medicine.

[36]  T. Lovenberg,et al.  Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior , 1997, Regulatory Peptides.

[37]  I. Wakabayashi,et al.  Selective Corticotropin‐Releasing Factor Type 1 Receptor Antagonist Blocks Conditioned Fear‐Induced Release of Noradrenaline in the Hypothalamic Paraventricular Nucleus of Rats , 2000, Journal of neuroendocrinology.

[38]  J. Lélias,et al.  Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors , 1993, FEBS letters.

[39]  H. Ohata,et al.  Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. , 2002, European journal of pharmacology.

[40]  T. Stiger,et al.  A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. , 2008, The American journal of psychiatry.

[41]  Paul E. Sawchenko,et al.  Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress , 2000, Nature Genetics.

[42]  C. Nemeroff,et al.  CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. , 1987, The American journal of psychiatry.

[43]  R. Bonsall,et al.  Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. , 2000, JAMA.

[44]  Florian Holsboer,et al.  Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. , 2002, Molecular endocrinology.

[45]  G. Koob,et al.  Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat , 2002, Brain Research.

[46]  R. Anda,et al.  Relationship between multiple forms of childhood maltreatment and adult mental health in community respondents: results from the adverse childhood experiences study. , 2003, The American journal of psychiatry.

[47]  Dennis C. Choi,et al.  Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness , 2003, Frontiers in Neuroendocrinology.

[48]  D. Mary,et al.  Urocortin II Induces Nitric Oxide Production Through cAMP and Ca2+ Related Pathways in Endothelial Cells , 2009, Cellular Physiology and Biochemistry.

[49]  G. Koob,et al.  CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat , 2005, Psychopharmacology.

[50]  Florian Holsboer,et al.  Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. , 2008, European journal of pharmacology.

[51]  David Lovejoy,et al.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor , 1995, Nature.

[52]  Susan E. Murray,et al.  Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2 , 2000, Nature Genetics.

[53]  C. Nemeroff,et al.  Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. , 1988, Archives of general psychiatry.

[54]  G. Koob,et al.  Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist , 2003, Brain Research.

[55]  G. Chrousos,et al.  Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. , 2003, Journal of medicinal chemistry.

[56]  H. Anisman,et al.  Dysregulation in the Suicide Brain: mRNA Expression of Corticotropin-Releasing Hormone Receptors and GABAA Receptor Subunits in Frontal Cortical Brain Region , 2004, The Journal of Neuroscience.

[57]  M. Wong,et al.  Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. , 1999, Life sciences.

[58]  C. Nemeroff,et al.  Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects , 1993, Psychiatry Research.

[59]  Lin Lu,et al.  Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats. , 2001, European journal of pharmacology.

[60]  K. Lewis,et al.  Expression cloning of a human corticotropin-releasing-factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[61]  C. Nemeroff,et al.  Advances in the treatment of depression , 2011, NeuroRX.

[62]  G. Chrousos,et al.  Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. , 2000, Bioorganic & medicinal chemistry letters.

[63]  E. Bass,et al.  Clinical Characteristics of Women With a History of Childhood Abuse: Unhealed Wounds , 1997 .

[64]  R. V. Van Heertum,et al.  PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density? , 2007, Nuclear medicine and biology.

[65]  T. Lovenberg,et al.  CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. , 1995, Endocrinology.

[66]  Younglim Lee,et al.  Role of Corticotropin‐Releasing Factor Receptor‐1 in Opiate Withdrawal , 2000, Journal of neurochemistry.

[67]  A. Steiger,et al.  Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. , 2004, Journal of psychiatric research.

[68]  D. Gutman,et al.  The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress , 2003, Journal of Pharmacology and Experimental Therapeutics.

[69]  D. Hellhammer,et al.  Sex Specific Associations between Common Glucocorticoid Receptor Gene Variants and Hypothalamus-Pituitary-Adrenal Axis Responses to Psychosocial Stress , 2007, Biological Psychiatry.

[70]  M. Ekker,et al.  Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior , 2008, Molecular Psychiatry.

[71]  R. Mansbach,et al.  Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. , 1997, European journal of pharmacology.

[72]  Y. Zhang,et al.  Activation of corticotropin-releasing factor 2 receptor inhibits Purkinje neuron P-type calcium currents via G(o)alpha-dependent PKC epsilon pathway. , 2009, Cellular signalling.

[73]  K. Ressler,et al.  Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. , 2008, Archives of general psychiatry.

[74]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[75]  Florian Holsboer,et al.  Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Bonsall,et al.  Altered Pituitary-Adrenal Axis Responses to Provocative Challenge Tests in Adult Survivors of Childhood Abuse , 2001 .

[77]  H. Mayberg.  Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. , 2003, British medical bulletin.

[78]  T. Lovenberg,et al.  Corticotrophin-releasing factor receptors: from molecular biology to drug design. , 1996, Trends in pharmacological sciences.